Welcome to our dedicated page for Conmed SEC filings (Ticker: CNMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Robotic shavers for arthroscopic surgery, energy platforms that reduce tissue damage, and patient monitoring systems spanning five continents—all of these sit inside Conmed’s wide-ranging product portfolio. That diversity makes its regulatory disclosures dense. Whether you’re hunting for FDA clearance updates, forecasting disposable instrument demand, or tracking raw-material costs, Conmed annual report 10-K simplified insight is the starting point. Stock Titan curates every page so you can move straight to the sections that matter.
Our AI models read each Conmed quarterly earnings report 10-Q filing and surface shifts in segment revenue, gross margin and R&D spend before the conference call ends. Real-time alerts flag Conmed Form 4 insider transactions real-time, turning routine Conmed executive stock transactions Form 4 into actionable signals. Need governance details? The platform links directly to the Conmed proxy statement executive compensation tables, while our natural-language summaries translate the legalese. From warranty-accrual changes in an 8-K to new shelf registrations, Conmed SEC filings explained simply are only a click away.
Investors use these tools to:
- Compare orthopedics and endoscopic segment trajectories quarter over quarter through Conmed earnings report filing analysis.
- Monitor supply-chain disclosures and product-liability reserves when Conmed 8-K material events explained appear between quarters.
- Spot buying patterns by surgeons-turned-executives via Conmed insider trading Form 4 transactions.
Sitting on top of EDGAR’s feed, Stock Titan refreshes the moment a document drops, then delivers concise AI-powered summaries, red-line comparisons and keyword search across the entire archive. If you’ve ever wrestled with understanding Conmed SEC documents with AI, this page ends that struggle—empowering you to act quickly, ask sharper questions and keep your focus on surgical innovation, not paperwork.
Fuller & Thaler Asset Management, Inc. filed a Schedule 13G reporting beneficial ownership of 1,740,630.07 shares of Conmed Corp common stock, representing 5.63% of the class. The filer reports sole voting power for 1,714,377.07 shares and sole dispositive power for 1,740,630.07 shares, with no shared voting or dispositive power disclosed.
The filing states these securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. Fuller & Thaler acts as investment adviser to the underlying accounts that own the shares.
Todd W. Garner, Executive Vice President & CFO of CONMED Corp (CNMD), reported a single insider sale. On 08/07/2025 he sold 598 shares of CONMED common stock at $52.45 per share, and the Form 4 reports he beneficially owns 0 shares following the transaction. The Form 4 was signed via power of attorney on 08/08/2025.
CONMED Corporation announced its Board declared a quarterly cash dividend of $0.20 per share. The dividend was declared on August 7, 2025 and is payable on October 3, 2025 to shareholders of record as of September 15, 2025. This is a cash distribution to owners of the company and represents a direct return of capital to shareholders for the quarter.
The current 8-K contains only the dividend declaration and payment details; it does not disclose earnings, changes to dividend policy, or other financial metrics. Investors seeking additional context on the company’s payout history or cash position will need to consult recent periodic reports or investor presentations.
FAQ
What is the current stock price of Conmed (CNMD)?
What is the market cap of Conmed (CNMD)?
